Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2007-09-18
2007-09-18
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
Reexamination Certificate
active
10240917
ABSTRACT:
The hepatitis B virus (HBV) capsid is made up of a single species of protein called the core antigen (HBcAg) which self-assembles into particles. The particles are highly immunogenic and are able to present heterologous epitopes to the immune system when the epitopes are inserted into a surface-exposed region of the particles called the “e1 loop”. The structural building blocks of the particles are tightly associated dimers of HBcAg in which the adjacent e1 loops are closely juxtaposed. It is proposed that sequences inserted into the e1 loop are conformationally restrained in the assembled particles when presented in monomeric core protein. The invention seeks to solve this problem by covalently linking core proteins as tandem copies (e.g., as dimers) so that insertions can be made independently in each copy. This is particularly useful for insertion of large sequences into the e1 loop because it allows such sequences to be inserted into just one copy of the core protein per tandem repeat, thereby reducing potential conformational clashes in assembly. Alternatively, a different sequence may be inserted into each e1 loop of a tandem repeat, thus increasing the flexibility of HBcAg particles as an epitope delivery system.
REFERENCES:
patent: 5969126 (1999-10-01), Potter et al.
patent: 6180343 (2001-01-01), Anderson et al.
patent: 2003/0021804 (2003-01-01), Needleman et al.
patent: 2004/0054139 (2004-03-01), Page et al.
patent: 2004/0106174 (2004-06-01), Jones et al.
patent: 2004/0156863 (2004-08-01), Page et al.
patent: 0421635 (1991-04-01), None
patent: WO97/35008 (1997-09-01), None
Kratz et al. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. USA, 1999, vol. 96, pp. 1915-1920.
Schodel et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. Journal of Virology. Jan. 1992, vol. 66, No. 1, p. 106-114.
Schodel et al. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. Presentation of foreign epitopes. Journal of Biotechnology. 1996, vol. 44, p. 91-96.
Kratz et al. “Native display of complete foreign protein domains on the surface of hepatitis B virus capsids” Proceedings of the National Academy of Sciences U.S.A., 96:1915-1920 (Mar. 1999).
Ulrich et al., “Core particles of hepatitis B virus as carrier for foreign epitopes” Advances in Virus Research, 50:141-182 (1998).
Gehin Annick
Gilbert Robert
Rowlands David
Stuart David
Campell Bruce R.
Le Emily M.
Nixon & Vanderhye P.C.
University of Leeds Innovations Limited
LandOfFree
Hepatitis B core antigen fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis B core antigen fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis B core antigen fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3783654